AA
ALLO icon

ALPS Advisors’s Allogene Therapeutics ALLO Stock Holding History

ALPS Advisors’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-175,285
Closed -$491K – 993
2024
Q3 		$491K Buy
175,285
+12,427
+8% +$33.1K ﹤0.01% 615
2024
Q2 		$379K Buy
162,858
+44,172
+37% +$130K ﹤0.01% 665
2024
Q1 		$531K Buy
118,686
+32
+0% +$134 ﹤0.01% 586
2023
Q4 		$381K Sell
118,654
-5,064
-4% -$14.4K ﹤0.01% 708
2023
Q3 		$392K Buy
123,718
+16,515
+15% +$72.4K ﹤0.01% 628
2023
Q2 		$533K Buy
+107,203
New +$580K ﹤0.01% 603
2022
Q4 		– Sell
-78,536
Closed -$848K – 1024
2022
Q3 		$848K Sell
78,536
-6,654
-8% -$90.4K 0.01% 499
2022
Q2 		$971K Buy
+85,190
New +$756K 0.01% 482

Other funds holding ALLO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

ALPS Advisors's ALLO Position: Q4 2024 in Review

ALPS Advisors sold out of Allogene Therapeutics (ALLO) in Q4 2024, closing a stake of 175,285 shares — an estimated $491K sold.

ALPS Advisors first reported a position in ALLO in Q2 2022 and held it in 8 quarters. The position peaked at $971K in Q2 2022. 174 funds tracked by Wall St. Rank hold ALLO as of Q4 2024.

  • ALPS Advisors reported no remaining Allogene Therapeutics position as of Q4 2024 after selling out during the quarter.
  • ALPS Advisors sold 175,285 Allogene Therapeutics shares in Q4 2024, an estimated $491K.
  • ALPS Advisors first reported a position in Allogene Therapeutics in Q2 2022 and held it in 8 quarters.
  • ALPS Advisors's Allogene Therapeutics position peaked at $971K in Q2 2022.
  • 174 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q4 2024.

Based on ALPS Advisors's 13F filing for Q4 2024, filed 13 Feb 2025.